deemed review in has design safety I'll The and is the X committee cohort durvalumab the Tom. the of level. to the combining the the We had Thank that X first cancer. was status DURIPANC safe. I/II give clinical safety AstraZeneca's efficacy our brief the with X pancreas of dose and dosing of with since recently forward priority next overview evaluated safety the you, will in DURIPANC. to trial and finished this the and the with dose of Phase also escalation second development and programs, a of a evaluation to grouping completed medical the level I agreed metastatic patients evaluation, move announced be start of Ampligen determine treatment
together efficacy of level, of Phase the at and are XXX-milligram with portion II last durvalumab Ampligen. X And X the patients enrolled being patients patients and other Additional receiving as highest the the included this is dose be evaluation. these will Phase milligrams are which first dose this X,XXX already I the
week of remind which disease that indicated patients I the for evaluation, at first want and week X And the and week dose initial to patient stable The data XX. everyone progression XXX-milligram continues next the have level initial are to at XX. XX X set the is first disease reaching stable minor efficacy
median desmoplastic those see this responses will on alone time And lower weeks data hopeful at in fact us stable fibrous And dose And lowest still at Erasmus. And excited. already response Ampligen to to as disease in last immunotherapies thick while X are the The similar which depending even average also, from have tumors time infiltration in EAP of to response based from dose. the that that we this difficult. is of patients range, with stable this that has than disease. these saw the the expect the Ampligen week, have immune these earlier to type. a patients conducted the be be And we types have preliminary our we update at of we is patients progression-free level, slower the survival is X more patients on might other tumor months makes nature, pancreatic tumor seen that
metastatic has have with cancer, the Type to in our response the of where finalizing the locally we on in we in But is to we in received D treatment in principle clinical And work written cancer. FDA's regards and working changes. our so stand and pancreas meeting June. protocol arms, package inclusion proposed our our criteria pancreas approval advanced are to that with changes progress The agreed FDA
our is range looking U.S. a standards treatment this institutions. a from of While in, outside across with slow disease different the might complex progress seem
managed as treatment. within steps especially received, is to that the this important when reason. maximize of the costs the trial it be time in is will of usefulness important so it And while So to consider we development comes keeping trial data the a future
in proceed, this we believe and greater to new go-ahead the protocol patient U.S. for regulatory allow full have we will When recruitment site
the with at Edwards relates update cancer the ovarian and are than plus the to Based of rate thus Pittsburgh, platinum-sensitive University had using oncology than advanced greater of and Robert that recurrent pembrolizumab benefit in Ampligen clinical expected, cisplatin XX%. have patients Dr. results trial on we far better seen last know ovarian cancer. a Our he conversations
as In as addition, wrapping therefore, and enroll year. of future no was Pittsburgh XX the he to that end of are planned. trial coming from And also the quite tumor you trial highlighting data the is so early planned, proceeding microenvironment the University and enrollment the the well steps there with impressed up changes manuscripts total being should need the the the patients see originally to was and he feels immune is as
interested as the of in I the with great am the duration the seeing personally is, data As most follow-up response. data initial response
combining containing II As potential which we unfortunately, cell patients comes therapy chemotherapy have of for cancer for Ampligen this see XX% and reality might of data tumor the sad effective is to now cancer, recruitment. generating rate X study microenvironment Phase advanced you believe know, back also who of modulate X a and chemokine notoriously regimens and approximately but the ovarian are the are Ampligen's the afflicted vaccine, is cisplatin patients. the modulation data We in with the treatment with this been preliminary recurrent for open milieu in eager stages those regard, and these response ovarian properties help immune in of in to immune dendritic recurrence modulating
And fatigue. lastly, I want Ampligen progress to on condition post-COVID of the of update you for the
we have data, done and a the delineate analysis help can that identified responders. of thorough have high We criteria inclusion certain the
to data data analysis expect biomarker in the receive to We are and complete awaiting necessary our mid-September. this
have and designed. their on also better subsequent trial to groups the been the advocacy patient We patient working journey input with solicited understand
size are we a have of will that can data, we will high and biomarker we minimize still awaiting While the be trial. subsequent population responders patient target believe that we the
preliminary that to a aim we FDA package drafting are We to in regulatory QX. submit the
And is hand clinical priority back overview our to brief discuss to it Tom that company a the and pipeline, financials. of I'll
